BHS Educational Course on Hodgkin lymphoma and aggressive lymphoma Special situations
|
|
- Earl Flynn
- 5 years ago
- Views:
Transcription
1 BHS Educational Course on Hodgkin lymphoma and aggressive lymphoma Special situations Daan Dierickx BHS Educational Course Seminar 12 Hof Ter Musschen, 7th March 2015
2 Special situations Primary central nervous system lymphoma (PCNSL) Posttransplant lymphoproliferative disorder (PTLD) AIDS related lymphoma (ARL)
3 Special situations Primary central nervous system lymphoma (PCNSL) Posttransplant lymphoproliferative disorder (PTLD) AIDS related lymphoma (ARL)
4 PCNSL definition and incidence Extranodal NHL limited to CNS (brain, cranial nerves, leptomeninges, CSF, intraocular structures, spinal cord) no systemic involvement (= secondary CNS lymphoma) Rare: <1% of all NHL 2-3% of all brain tumors
5 Question 1 What s the most important risk factor for development of PCNSL?
6 PCNSL risk factors Immunodeficiency states Congenital Acquired PTLD HIV EBV Immune competent patients Villano JL, et al. Br J Cancer 2011;105:
7 >95% DLBCL PCNSL presentation 20% intraocular involvement (rare: PIOL) Golden standard for diagnosis: stereotactic biopsy (ideal: without steroids) Staging: MRI brain with gadolinium (PET?+) CT whole body Bone marrow examination Slit lamp examination
8 PCNSL presentation Wang CC, et al. Br J Haematol 2014;166:311-25
9 PCNSL prognostic scores The International Extranodal Lymphoma Study Group (IELSG) prognostic index (0-5 scale) : Age > 60 yr, performance state (ECOG 2), LDH, elevated protein concentration in CSF and involvement of deep brain structures The Nottingham/Barcelona prognostic score (0-3 scale): Age >60 yr, performance state (ECOG 2), multifocal disease The Memorial Sloan Kettering Cancer Center (MSKCC) prognostic score (0-2 scale): : Age > 50 yr, performance state (ECOG 2) Ferreri AJ, et al. J Clin Oncol 2003;21: Bessell EM, et al, Int J Radiat Oncol Biol Phys 2004;59:501-8 Abrey LE, et al, J Clin Oncol 2006;24:5711-5
10 Question 2 Which therapeutic regimen is the backbone in the treatment of PCNSL?
11 PCNSL treatment Median OS: 12 months Majority (88%) of recurrences: within boost field Major problem: delayed neurotoxicity (especially > 60 years) Nelson DF, et al. Int J Radiat Oncol Biol Phys 1992;23:9-17
12 PCNSL adding chemotherapy to WBRT CHOD no survival benefit BBB HD-MTX based chemotherapy Marked survival benefit: median OS months Late neurotoxicity (up to 25%) Abrey L, et al. J Clin Oncol 2000;18: DeAngelis LM, et al. J Clin Oncol 2002;20:4643-8
13 PCNSL eliminating WBRT Multiple retrospective and prospective phase 2 trials: inferior outcomes Only 1 prospective phase 3 study: G-PCNSL-SG-1 trial Thiel E, et al. Lancet Oncol 2010;11:
14 PCNSL G-PCNSL-SG-1 trial: long term follow up Thiel E, et al. Lancet Oncol 2010;11: Korfel A, et al. Neurology 2015 Feb 25, [Epub ahead of print]
15 PCNSL G-PCNSL-SG-1 trial: long term follow up Thiel E, et al. Lancet Oncol 2010;11: Korfel A, et al. Neurology 2015 Feb 25.[Epub ahead of print]
16 PCNSL alternatives to WBRT Reduced dose radiotherapy (23.4 Gy) High dose therapy with autologous stem cell transplantation Non-myeloablative chemotherapy (etoposidecytarabine) Morris PG, et al. J Clin Oncol 2013;31: Omuro A, et al. Blood 2015 Jan 7. [Epub ahead of print] Rubenstein JL, et al. J Clin Oncol 2013;31:3061-8
17 Rituximab? PCNSL other questions Intrathecal chemotherapy?
18 PCNSL treatment Young, fit patients MTX 3,5 gr/m² day 1 Cytarabine 2 x 2 gr/m² day 2 and 3 Every 3 weeks Four cycles Followed by WBRT if no CR after 1 cycle HDT + ASTx Ferreri AJM, et al. Lancet 2009;374:
19 Elderly PCNSL EORTC protocol 1. First cycle (induction chemotherapy) IV MTX 1 g/m 2 days 1, 10, 20 PO lomustine 40 mg/m 2 day 1 PO procarbazine 60 mg/m 2 days 1 7 IV or PO methylprednisolone 120 mg/m 2 every other day from days 1 20 and 60 mg/m 2 days (IT methotrexate 15 mg and cytarabine 40 mg days 1, 5, 10, and 15) 2. If SD or PD: stop PCNSL treatment 3. If CR or PR: five more cycles every 6 weeks (maintenance chemotherapy) IV methotrexate 1 g/m 2 day 1 PO lomustine 40 mg/m 2 day 1 PO procarbazine 60 mg/m 2 days 1 7 (IT methotrexate 15 mg and cytarabine 40 mg day 1) Hoang-Xuan K, et al. J Clin Oncol 2003;21:
20 Special situations Primary central nervous system lymphoma (PCNSL) Posttransplant lymphoproliferative disorder (PTLD) AIDS related lymphoma (ARL)
21 Gruhlich AE et al. Lancet 2007;370:59-67
22 Risk factors Type of transplanted organ EBV status at time of transplantation (recipient negative/donor positive) Intensity/duration of immunosuppressive therapy Underlying disorder Infectious agents other than EBV (CMV?, HCV?) Age of donor and recipient Number and severity of rejection episodes Cytokine gene polymorphisms HLA alleles/haplotypes/mismatches/antibodies
23 Question 3 Which organ transplantation is associated with the lowest risk for development of PTLD?
24 Risk factors: 1. organ type Organ Number of transplantations (% men) Number of PTLDs % of PTLDs Organ specific incidence (%) Kidney 3566 (59%) Liver 853 (53%) Lung 568 (53%) Heart 519 (80%) HSCTx 1092 (59%) Total 6598 (60%) Dierickx D, et al. Leuk Lymphoma 2013;54:
25 Risk factors: 2. EBV status Mismatch (donor seropositive / receptor seronegative): significant increased risk (10-75x) = most important risk factor EBV naive patients: higher risk explains higher incidence in childhood EBV naive patients: Often initially presentation with EBV-associated PTLD type early lesions or polymorfic type Often early onset PTLD Remains risk factor Shahinian VB, et al. Transplantation 2003;75:851-6
26 Risk factors: 3. immunosuppressive therapy Halloran PF. New Engl J Med 2004;351:
27 Risk factors: 3. immunosuppressive therapy Association Controversial No association Tacrolimus Azathioprin ATG OKT3 Belatacept Efalizumab EBV+ Tofacitinib Cyclosporin A mtor inhibitors MMF Alemtuzumab Basiliximab/daclizumab
28 Pathogenesis 67%: EBV-associated PTLD Deficient EBV specific cellular immune response SOT: immune suppressive medication HSCTx: conditioning, T cell depletion and immune suppressive medication 33%: EBV-negative PTLD Pathogenesis less clear Therapy similar (except for EBV-targeted therapy)
29 Rezk SA, et al. Hum Pathol 2007;38: Thorley Lawson DA. Nat Rev Immunol 2001; 1:75-82 Thorley-Lawson DA. J Allergy Clin Immunol 2005;116: Pathogenesis
30 Pathogenese Hawkins JB, et al. PLoS Pathog 2013;9(10):e
31 Saha A, Robertson E S Clin Cancer Res 2011;17: Pathogenesis
32 Pathogenesis: role of EBV IMMORTALIZATION Thorley Lawson DA. Nat Rev Immunol 2001;1:75-82
33 Classification: WHO 2008 Immunodeficiency Associated Lymphoproliferative Disorders Lymphoproliferative diseases associated with primary immune disorders Lymphomas associated with HIV infection Post-transplant lymphoproliferative disorders Other iatrogenic immunodeficiency-associated lymphoproliferative disorders Swerdlow H, et al. IARC Press: Lyon 2008
34 Classification: WHO 2008 POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS Early lesions Reactive plasmacytic hyperplasia Infectious mononucleosis-like Polymorphic PTLD Monomorphic PTLD B-cell neoplasms (DLBCL; BL; PCM; plasmacytoma-like lesions, other) T-cell neoplasms (PTCL,NOS; HSTCL; other) Hodgkin lymphoma/hodgkin-like lymphoma Jaffe ES, et al. IARC Press: Lyon 2008
35 Question 4 What is the critical step in the initial treatment of PTLD?
36 Treatment Gottschalk, et al. Annu.Rev.Med 2005;56:29-44
37 Treatment Gottschalk, et al. Annu.Rev.Med 2005;56:29-44
38 Treatment Gottschalk, et al. Annu.Rev.Med 2005;56:29-44
39 Treatment: restoring T cell function 1. Reduction of immune suppression (RIS) PTLD = excess immune suppression No consensus/uniform guidelines: STOP antimetabolites Reduce CNI dose Continue or increase steroids 1-4 weeks response rates: 0 - >50% Highest response rates: Early lesions EBV positive
40 Treatment: restoring T cell function 1. Reduction of immune suppression (RIS) Treatment Overall response rate (CR) Pennsylvania RIS only 45% (37%) Baltimore Sequential therapy (RIS IFNα chemo) 6% (0%) Reshef R, et al. Am J Transplant 2011;11: Swinnen LJ, et al. Transplantation 2008;86:215-22
41 Treatment: restoring T cell function 1. Reduction of immune suppression (RIS) Organ dependent Kidney: dialysis rescue Hematopoietic stem cell: less efficious Heart: risk sudden death Aull MJ, et al. Transplantation 2004;78: Switch to mtor inhibition? Currently very controversial
42 2. Adoptive immunotherapy Treatment: restoring T cell function EBV specific CTLs Kennedy-Nasser AA, et al. Mediterr J Hematol 2009;17;1(2):e
43 1. Chemotherapy Treatment: reduction of B cell mass Retrospective analysis IPITTR: PTLD following SOT n = 193 Regimen 5yrOS (%) PTLD-specific mortality (%) CHOP ProMACE Other multidrug Monotherapy 5 48 Buell JF, et al. Transplant Proc 2005;37:956-7
44 1. Chemotherapy Treatment: reduction of B cell mass Immuno-chemotherapy (Rituximab + CHOP): standard of care in immune competent patients PTLD: higher TRM (infections) Solutions? Better supportive care G-CSF, anti-infectious agents Low dose chemotherapy Sequential therapy Only 1 prospective study in children
45 Treatment: reduction of B cell mass 2. Monoclonal anti-b cell antibodies Stamataki Z, et al. PLoS One 2011;6:e25789
46 Prospective studies: Treatment: reduction of B cell mass 2. Monoclonal anti-b cell antibodies Author Year Phase n ORR(%) Oertel 2005 II Blaes 2005 II Choquet 2006 II Gonzalez-Barca * 2007 II (CRR) In most studies: rituximab 375 mg/m²/week during 4 consecutive weeks * risk adapted extended treatment (PR): upgrading CR 34% 60.5%
47 Treatment: reduction of B cell mass 2. Monoclonal anti-b cell antibodies Rituximab or chemotherapy? No prospective randomized trials Retrospective analysis (Pennsylvania University) n = 35 (34 SOT, 1 HSCTx) 22 R, 23 chemo Rituximab: RR 68%, OS 31 months Chemotherapy: RR 72%, OS 42 months Rituximab: excellent tolerance; chemotherapie TRM 26% Treatment failure after rituximab: salvage with chemotherapy later Important: better performance status following rituximab Elstrom RL, et al. Am J Transpl 2006;6:569-79
48 Treatment: reduction of B cell mass PTLD1 trial Sequential Treatment Trappe R, et al. Lancet Oncol 2013;13:
49 Percent OS Treatment: reduction of B cell mass PTLD1 trial 100 p= CR or PR after 4 cycles of rituximab (n=35) SD or PD after 4 cycles of rituximab (n=23) Months
50 Treatment: reduction of B cell mass PTLD1 trial Risk Stratified Sequential Treatment
51 Treatment Zimmermann H, Trappe R. Hematology Am Soc Hematol Educ Program 2013;2013:95-102
52 Prophylaxis/prevention/preemptive Problems Who? High risk patients Definition? Which test? How? EBV PCR, FLC(?), scxcl13 RIS Rituximab Adoptive immunotherapy Source? Cut off? Increase? Mostly retrospective single center data
53 Prophylaxis/prevention/preemptive Rasche L, et al. Bone Marrow Transplant 2014;49:163-7
54 Prophylaxis/prevention/preemptive Choquet S, et al. Am J Transplant 2014;14:857-66
55 Special situations Primary central nervous system lymphoma (PCNSL) Posttransplant lymphoproliferative disorder (PTLD) AIDS related lymphoma (ARL)
56 Classification: WHO 2008 Immunodeficiency Associated Lymphoproliferative Disorders Lymphoproliferative diseases associated with primary immune disorders Lymphomas associated with HIV infection Post-transplant lymphoproliferative disorders Other iatrogenic immunodeficiency-associated lymphoproliferative disorders Swerdlow H, et al. IARC Press: Lyon 2008
57 Question 5 Is the incidence of ARL increasing or decreasing?
58 ARL incidence Gruhlich AE et al. Lancet 2007;370:59-67
59 ARL subtypes Carbone A, et al. Nat Rev Clin Oncol 2014;11:223-38
60 Franceschi S, et al. Br J Cancer 2010;103:416-22
61 ARL treatment and prognosis Treatment: Early initiation of cart (during chemotherapy) Lymphoma-specific treatment Supportive care New treatment strategies needed (PEL, PBL) Prognostic factors: Low CD4 count, poor PS aaipi, histological subtype
62 ARL treatment and prognosis Barta SK, et al. Ann Oncol 2015 [Epub ahead of print]
63 ARL treatment DLBCL DLBCL: R-CHOP or R-EPOCH Barta SK, et al. Ann Oncol 2015 [Epub ahead of print]
64 Montoto S, et al. J Clin Oncol 2012;30: Hentrich M, et al, J Clin Oncol 2012;30: Uldrick TS, Little RF. Blood 2015;125: ARL treatment HL Mostly advanced stage Higher CD4 counts EBV associated Subtype: NS, LD and MC HL: ABVD
65 ARL treatment BL BL: short intensive chemotherapy + rituximab Galicier L, et al. Blood 2007;110: Xicoy B, et al, Leuk Lymphoma 2014;55:2341-8
66 ARL treatment BL BL: short intensive chemotherapy + rituximab or SC-EPOCH-RR? Dunleavy K, et al, N Engl J Med 2013;369:
67 ARL treatment PCNSL: HD MTx/Ara-C +/- RT PBL and PEL: very poor prognosis PBL and PEL: new treatments needed Castillo JJ, et al, Cancer 2012;118: Schommers P, et al. Br J Haematol 2014 Nov 17.[Epub ahead of print]
68
IAN CROCKER = TIM HOWARD
Winship Cancer Institute of Emory University Radiation as Consolidation in the Treatment of Newly Diagnosed CNS Lymphoma versus After Failure of Chemotherapy Pro: Upfront Radiation Ian Crocker MD, FACR,
More informationNephrology Grand Rounds
Nephrology Grand Rounds PTLD in Kidney Transplantation Charles Le University of Colorado 6/15/12 Objectives Background Pathogenesis Epidemiology and Clinical Manifestation Incidence Risk Factors CNS Lymphoma
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationLymphomas in the immunocompromised patient
Lymphomas in the immunocompromised patient Daan Dierickx 10 February 2017 32 nd General Annual Meeting of the Belgian Hematology Society Dolce La Hulpe, Brussels Immunodeficiency-associated Lymphoproliferative
More informationDisclosure for Ralf Trappe, MD
Disclosure for Ralf Trappe, MD In compliance with ACCME policy, ASH requires the following disclosures to the session audience: Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau
More informationLYMPHOMA in HIV PATIENTS. Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma
LYMPHOMA in HIV PATIENTS Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma Lugano, 3-4 November 2017 Disclosures: Roche: honoraria Gilead: travel grant ESMO Preceptorship
More informationWork-up and management of a high-risk patient with primary central nervous system lymphoma
Cancer Biol Med 2016. doi: 10.20892/j.issn.2095-3941.2016.0070 CASE REPORT Work-up and management of a high-risk patient with primary central nervous system lymphoma Pervin A. Zeynalova 1, Gayane S. Tumyan
More informationTreating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma
Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy Treating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma Raul Cordoba, MD, PhD Lymphoma Unit
More information10/31/2017. Immunodeficiencies. Outline. Discuss EBV. Non-destructive Polymorphic Monomorphic Therapies Challenges
I have no financial disclosures Joo Y. Song, MD Assistant Professor of Clinical Pathology City of Hope National Medical Center Immunodeficiencies Outline Transplant Congenital Autoimmunity T-cell/immune
More information11/2/2017. Immunodeficiencies. Joo Y. Song, MD Assistant Professor of Clinical Pathology. I have no financial disclosures.
I have no financial disclosures Joo Y. Song, MD Assistant Professor of Clinical Pathology City of Hope National Medical Center Immunodeficiencies Transplant Autoimmunity Drugs T-cell dysfunction (Age,
More informationNK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital
NK/T cell lymphoma Recent advances Y.L Kwong University Department of Medicine Queen Mary Hospital Natural killer cell lymphomas NK cell lymphomas are mainly extranodal lymphomas Clinical classification
More informationHIV ASSOCIATED LYMPHOMA. Dr N Rapiti
HIV ASSOCIATED LYMPHOMA Dr N Rapiti HIV ASSOCIATED LYMPHOMA: OVERVIEW Classification Pathogenesis Prognosis cart Chemotherapy/Radiotherapy/SCT Supportive CASE 40 yr old male, Mr BM, p/w Symptomatic anemia
More informationInduction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Di... Advertisement
Page 1 of 5 Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. EBV Post Transplantation Implications and Approach to Management
2017 CST-Astellas Canadian Transplant Fellows Symposium EBV Post Transplantation Implications and Approach to Management Atul Humar, MD Atul Humar is a Professor in the Department of Medicine, University
More informationPeripheral T-cell lymphoma. Matt Ahearne Clinical Lecturer, Leicester
Peripheral T-cell lymphoma Matt Ahearne Clinical Lecturer, Leicester PTCL Objectives To understand the natural history of PTCL To appreciate the importance of accurate diagnosis of PTCL including recent
More informationEBV in HSCT 2015 update of ECIL guidelines
ECIL-6 EBV in HSCT 2015 update of ECIL guidelines Jan Styczynski (Poland, chair), Walter van der Velden (Netherlands), Christopher Fox (United Kingdom), Dan Engelhard (Israel), Rafael de la Camara (Spain),
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationASCO abstract June 2007 :Othieno-Abinya NA, Abwao HO, Kiarie GW)
Inferior outcome of poor prognostic phenotype non- Hodgkin s lymphoma treatment among HIV positive patients compared with HIV negative counterparts in the HAART era. (ASCO abstract June 2007 :Othieno-Abinya
More informationPrimary Intraocular Lymphoma (PIOL)
Primary Intraocular Lymphoma (PIOL) Ref: Ryan SJ et al. Retina 5 th ed., original and review articles 眼科医局勉強会 岩崎優子 2016/7/4 PIOL and primary central nervous system lymphoma (PCNSL) Non-Hodgkin s Lymphoma
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationHave we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!
Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine
More informationAn Update on Therapy of Primary Central Nervous System Lymphoma
An Update on Therapy of Primary Central Nervous System Lymphoma Lisa M. DeAngelis and Fabio M. Iwamoto Primary central nervous system lymphoma (PCNSL) is an extranodal non-hodgkin lymphoma (NHL) that arises
More informationCharacteristics and Outcomes of Elderly Patients With Primary Central Nervous System Lymphoma
Characteristics and Outcomes of Elderly Patients With Primary Central Nervous System Lymphoma The Memorial Sloan-Kettering Cancer Center Experience Douglas E. Ney, MD 1 ; Anne S. Reiner, MPH 2 ; Katherine
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationRichter s Syndrome: Risk, Predictors and Treatment
Richter s Syndrome: Risk, Predictors and Treatment 10/23/2015 John N. Allan MD Assistant Professor of Medicine Division of Hematology and Medical Oncology CLL Research Center Weill Cornell Medicine Agenda
More informationPros and Cons: Interim PET in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen
3rd International Workshop on in Lymphoma Menton, September 26, 2011 Afternoon Controversies Pros and Cons: in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen Pros Is there any
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationCNS Lymphoma. Las Vegas-- March 10-12, 2016
CNS Lymphoma Las Vegas-- March 10-12, 2016 Frequency 3% of primary cerebral tumors 1% of NHLs Recent developments and controversies in PCNSL Hottinger et al Current Opinion in Oncology Vol 27 No. 6 November
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationPrimary central nervous system lymphoma (PCNSL)
Neuro-Oncology 14(10):1304 1311, 2012. doi:10.1093/neuonc/nos207 Advance Access publication September 5, 2012 NEURO-ONCOLOGY Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial
More informationManagement of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Management of Primary Central Nervous System Diffuse Large B-Cell Lymphoma G. Fraser, N.P. Varela, J. Dudebout
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 24 AUGUST 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationTherapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database
REGULAR ARTICLE Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database Jaleh Fallah, 1,2 Lindor Qunaj, 1 and Adam J. Olszewski 1,3
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationFirst Line Management of Classical Hodgkin Lymphoma
First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /
More informationTransformed lymphoma: biology and treatment
Transformed lymphoma: biology and treatment Silvia Montoto Centre for Haemato-Oncology Barts Cancer Institute 1.00 0.75 0.50 0.25 0.00 N =330 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 Years %Viability
More informationLYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France
LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationPulczynski, Elisa J
https://helda.helsinki.fi Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance Pulczynski,
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationLymphoma- Med A-new drugs and treatments
Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationRecent Advances in Treatment of Primary Central Nervous System Lymphoma
Current Treatment Options in Oncology (2013) 14:539 552 DOI 10.1007/s11864-013-0252-6 Neuro-oncology (GJ Lesser, Section Editor) Recent Advances in Treatment of Primary Central Nervous System Lymphoma
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 7 MARCH 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Results of Whole-Brain Radiation As Salvage of Methotrexate Failure for Immunocompetent Patients With Primary CNS
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationUNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE
UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest
More informationUPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.
More informationHaploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy
Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes
More informationMethotrexate-associated Lymphoproliferative Disorders
Methotrexate-associated Lymphoproliferative Disorders Definition A lymphoid proliferation or lymphoma in a patient immunosuppressed with methotrexate, typically for treatment of autoimmune disease (rheumatoid
More informationTreatment Landscape in R/R DLBCL Novel Targets and Strategies. Wyndham H. Wilson, M.D., Ph.D. Senior Investigator
Treatment Landscape in R/R DLBCL Novel Targets and Strategies Wyndham H. Wilson, M.D., Ph.D. Senior Investigator Gene-expression profiling of DLBCL subtypes Roschewski, M. et al. (2013) Nat. Rev. Clin.
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationOutcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions
Outcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions AA Moccia, S Gobba, A Conconi, S Diem, L Cascione, K Aprile von Hohenstaufen, W Gulden Sala, A Stathis, F Hitz, G Pinotti,
More informationAggressive B-cell lymphomas and gene expression profiling towards individualized therapy?
Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION
More informationEFFICACY AND SAFETY OF TABELECLEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED LEIOMYOSARCOMAS (EBV + LMS)
EFFICACY AND SAFETY OF TABELECLEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED LEIOMYOSARCOMAS (EBV + LMS) Lauren S. Kurlander, 1 Ashok Srinivasan, 2 Armin Ghobadi, 3 Stephanie Suser, 4 Ekaterina
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationProfessor Mark Bower
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Professor Mark Bower Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Mark Bower
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More information1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationSociety for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationEBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda
EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction
More informationAcute GVHD. ESH-EBMT 2009 Latimer A. Devergie
Acute GVHD ESH-EBMT 2009 Latimer A. Devergie Acute GVHD Activated Donor T cells damage host epithelial cells after an inflammatory cascade that begins after the preparative regimen GVHD is the major barrier
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More information21/07/2017. Lymphoproliferations in immunodeficiency. IBD and EBV associated LPD in GIT Han van Krieken. Inflammatory bowel disease and cancer
IBD and EBV associated LPD in GIT Han van Krieken Lymphoproliferations in immunodeficiency Primary immunodeficiencies Large variation in conditions and lesions Acquired immunodeficiencies HIV: changes
More informationDisclosures. CMV and EBV Infection in Pediatric Transplantation. Goals. Common Aspects CMV (Cytomegalovirus) and EBV (Epstein-Barr virus)
Disclosures I have financial relationships with the following companies: CMV and EBV Infection in Pediatric Transplantation Elekta Inc Lucence Diagnostics Spouse employed Spouse employed I will not discuss
More informationSevere Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia
Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia Liat Shragian Alon, MD Rabin Medical Center, ISRAEL #EBMT15 www.ebmt.org Patient: 25-year-old male No prior medical history
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationDr. Andrea Gallamini - Hematology Department Azienda Ospedaliera S. Croce e Carle Cuneo Italy
High-dose sequential chemotherapy (HDS) followed by autologous stem cell transplantation (ASCT) in relapsed/refractory Hodgkin s lymphoma. Long term results. Dr. Andrea Gallamini - Hematology Department
More information